07 - 08 July, 2020
| Online Event
Conference Day 2
10:20 am - 10:30 am
Chairman's Welcome and Summary of Day 1
10:30 am - 11:15 am
Transitioning Towards a Decentralised Manufacturing Strategy
Ohad Karnieli -
CEO,
ADVA Biotechnology
- Discuss how - and why - ADVA ave proactively moved from a centralised to decentralised manufacturing strategy
- Examine how decentralised manufacturing can alleviate the challenges posed by closing borders and ongoing flight cancellations
- Weigh up the costs of goods with the benefits of transitioning towards decentralisation with reference to logistics management, regulatory approval and speed of supply
- Identify critical elements to enable decentralized manufacturing
11:15 am - 12:00 pm
Session Reserved For Sponsor
12:00 pm - 12:45 pm
Looking at the Research Perspective: Translation under Covid-19 at UCL
Pamela Tranter -
Head of Translational Research Group,
UCL
- Outline the biggest challenges presented to UCL's translational model when identifying high potential candidates
- Discuss the role of academic research and translation in addressing the current pandemic environment, and the challenges inherent with timeline management
- Analyse how changes in industry priorities and broader governmental support an be used to maximise the relationship between the academic and private sectors to fast-track viable therapies into development
12:45 pm - 2:00 pm
Lunch Break
2:00 pm - 2:45 pm
Maintaining a C> Biotech through the COVID-19 Crisis: Challenges and Opportunities
Miguel Forte -
CEO,
Bone Therapeutics
- Engage with the bone Therapeutics perspective on the changes to clinical development for allogenic cell therapies under Covid-19
- Discuss strategies to re-enforce your clinical operations to mitigate against delays and maintain development consistency
2:45 pm - 3:30 pm
Session Reserved for Sponsor
3:30 pm - 4:15 pm
Case Study: Stem Cell Raw Materials Qualification at Novo Nordisk
Pernille Linnert Jensen -
Senior Scientist - Project Lead Stem Cell R&D,
Novo Nordisk
- How to balance safety, compliance and speed when qualifying raw materials for very different stem cell therapy purposes like cell banking or drug product manufacture for Clinical Phase I/II, Phase III or the Market?
